TY - JOUR
T1 - Reinnervation of motor endplates and increased muscle fiber size after human insulin-like growth factor I gene transfer into the paralyzed larynx
AU - Shiotani, A.
AU - O'Malley, Jr
AU - Coleman, M. E.
AU - Alila, H. W.
AU - Flint, P. W.
PY - 1998/9/20
Y1 - 1998/9/20
N2 - Current surgical strategies for the treatment of laryngeal paralysis are limited by the muscle atrophy associated with denervation. Moreover, attempts at reinnervation have not effected significant change in surgical outcome. To address this clinical problem, we have developed a rat laryngeal paralysis model to study novel gene transfer strategies. Using this model, the human insulin-like growth factor I (hIGF-I) gene was introduced into paralyzed rat laryngeal muscle to assess the benefit of sustained local hIGF-I production. A muscle-specific nonviral vector containing the α-actin promoter and hIGF-I gene was used in formulation with a polyvinyl-based delivery system and injected into paralyzed adult rat laryngeal muscle. Twenty-eight days after a single injection, gene transfer efficiency, muscle fiber size, motor endplate length, and nerve-to-motor endplate contact were evaluated. Gene transfer was detected in 100% of injected animals by PCR. Gene transfer with expression, as measured by RT-PCR for hIGF-I mRNA, occurred in 81.3% of injected animals. When compared with controls, hIGF-I-transfected animals presented a significant increase in muscle fiber diameter [17.56 (± 0.97 SD) μm versus 14.70 (± 1.43 SD) μm; p = 0.0002], a significant decrease in motor endplate length [20.88 (± 1.42 SD) μm versus 25.41 (± 3.19 SD) μm; P = 0.0025], and a significant increase in percentage of endplates with nerve contact (20.3% (± 13.9 SD) versus 4.4% (± 4.2 SD); p = 0.0079). In the context of laryngeal paralysis, gene therapy represents a tremendous opportunity to augment current surgical treatment modalities by preventing or reversing muscle atrophy, and by enhancing nerve sprouting and reinnervation.
AB - Current surgical strategies for the treatment of laryngeal paralysis are limited by the muscle atrophy associated with denervation. Moreover, attempts at reinnervation have not effected significant change in surgical outcome. To address this clinical problem, we have developed a rat laryngeal paralysis model to study novel gene transfer strategies. Using this model, the human insulin-like growth factor I (hIGF-I) gene was introduced into paralyzed rat laryngeal muscle to assess the benefit of sustained local hIGF-I production. A muscle-specific nonviral vector containing the α-actin promoter and hIGF-I gene was used in formulation with a polyvinyl-based delivery system and injected into paralyzed adult rat laryngeal muscle. Twenty-eight days after a single injection, gene transfer efficiency, muscle fiber size, motor endplate length, and nerve-to-motor endplate contact were evaluated. Gene transfer was detected in 100% of injected animals by PCR. Gene transfer with expression, as measured by RT-PCR for hIGF-I mRNA, occurred in 81.3% of injected animals. When compared with controls, hIGF-I-transfected animals presented a significant increase in muscle fiber diameter [17.56 (± 0.97 SD) μm versus 14.70 (± 1.43 SD) μm; p = 0.0002], a significant decrease in motor endplate length [20.88 (± 1.42 SD) μm versus 25.41 (± 3.19 SD) μm; P = 0.0025], and a significant increase in percentage of endplates with nerve contact (20.3% (± 13.9 SD) versus 4.4% (± 4.2 SD); p = 0.0079). In the context of laryngeal paralysis, gene therapy represents a tremendous opportunity to augment current surgical treatment modalities by preventing or reversing muscle atrophy, and by enhancing nerve sprouting and reinnervation.
UR - http://www.scopus.com/inward/record.url?scp=0032552424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032552424&partnerID=8YFLogxK
U2 - 10.1089/hum.1998.9.14-2039
DO - 10.1089/hum.1998.9.14-2039
M3 - Article
C2 - 9759931
AN - SCOPUS:0032552424
SN - 1043-0342
VL - 9
SP - 2039
EP - 2047
JO - Human Gene Therapy
JF - Human Gene Therapy
IS - 14
ER -